CFDB - Cystic Fibrosis DataBase

primary studies published, non RCT

Long-term evaluation of effectiveness for selected chest physiotherapy methods used in the treatment of cystic fibrosis.

Study design (if review, criteria of inclusion for studies)

Multicenter retrospective study

Participants

13 adults and adolescents with CFRD

Interventions

Tandem t:slim X2 pump with Control IQ™ technology, a HCL system.

Outcome measures

14 days of continuous glucose monitor data were analyzed at baseline, 1 and 3 months after transition to the Tandem t:slim X2 pump with Control IQ™ technology

Main results

Control IQ initiation was associated with a significant increase in % time in target range (70-180 mg/dL), as well as decreases in average glucose, % time in hyperglycemic ranges (% time >180 mg/dL, % time >250 mg/dL), and glycemic variability (standard deviation, coefficient of variation). There was no significant change in % time in hypoglycemia ranges (% time <54 mg/dL, % time <70 mg/dL).

Authors' conclusions

This is the first study to report a beneficial effect of Food and Drug Administration (FDA)-approved HCL technology on glycemia in adults and adolescents with CFRD to date. Future studies are needed to understand the potential long-term glycemic benefits of HCL devices and to explore the impact of this technology on heath-related quality of life, pulmonary function, nutritional status, and mortality.

Keywords: hybrid closed loop (HCL) technology; non pharmacological intervention - devices OR physiotherapy; Diabetes Mellitus; Pancreatic Diseases; Gastrointestinal Diseases;